Table 4.

Summary of H. pylori eradication by treatment arm and selected baseline characteristics for ITT population

Treatment Regimen	N	Eradicated		Difference from Standard Arm	Adjusted 95% CI	P-value for Interaction^*
Treatment Regimen	N	N	Percent	Difference from Standard Arm	Adjusted 95% CI	P-value for Interaction^*
Gender						0·91

Female	861

14-day Standard	287	234	81·5%	(referent)
5-day Concomitant	288	207	71·9%	9·7%	1·8%, 17·5%
10-day Sequential	286	214	74·8%	6·7%	−1·4%, 14·8%

Male	602

14-day Standard	201	167	83·1%
5-day Concomitant	201	153	76·1%	7·0%	−2·0%, 15·9%
10-day Sequential	200	158	79·0%	4·1%	−5·2%, 13·3%

Age						0·21

40 years or younger	663

14-day Standard	222	182	82·0%
5-day Concomitant	220	164	74·5%	7·4%	−1·3%, 16·2%
10-day Sequential	221	160	72·4%	9·6%	0·3%, 18·9%

Older than 40 years	800

14-day Standard	266	219	82·3%
5-day Concomitant	269	196	72·9%	9·5%	1·4%, 17·5%
10-day Sequential	265	212	80·0%	2·3%	−5·6%, 10·3%

Chronic Dyspeptic Symptoms						0·38

Absent	1090

14-day Standard	363	297	81·8%
5-day Concomitant	368	277	75·3%	6·5%	−0·2%, 13·3%
10-day Sequential	359	281	78·3%	3·5%	−3·4%, 10·5%

Present	373

14-day Standard	125	104	83·2%
5-day Concomitant	121	83	68·6%	14·6%	2·5%, 26·7%
10-day Sequential	127	91	71·7%	11·5%	−0·9%, 24·0%

Study Site						0·28

Santiago, Chile	209

14-day Standard	69	59	85·5%
5-day Concomitant	70	46	65·7%	19·8%	3·9%, 35·7%
10-day Sequential	70	59	84·3%	1·2%	−13·6%, 16·1%

Túquerres, Colombia	212

14-day Standard	71	58	81·7%
5-day Concomitant	72	58	80·6%	1·1%	−13·5%, 15·8%
10-day Sequential	69	54	78·3%	3·4%	−13·2%, 20·0%

Guanacaste, Costa Rica	210

14-day Standard	70	61	87·1%
5-day Concomitant	70	54	77·1%	10·0%	−4·4%, 24·4%
10-day Sequential	70	63	90·0%	−2·9%	−16·3%, 10·6%

Copán, Honduras	213

14-day Standard	70	66	94·3%
5-day Concomitant	72	62	86·1%	8·2%	−2·9%, 19·2%
10-day Sequential	71	58	81·7%	12·6%	−0·8%, 26%

Tapachula, México	210

14-day Standard	71	55	77·5%
5-day Concomitant	69	50	72·5%	5·0%	−11·4%, 21·4%
10-day Sequential	70	47	67·1%	10·4%	−7·9%, 28·5%

Ciudad Obregón, México	210

14-day Standard	70	54	77·1%
5-day Concomitant	69	47	68·1%	9·0%	−7·8%, 25·9%
10-day Sequential	71	47	66·2%	10·9%	−7·4%, 29·2%

León, Nicaragua	199

14-day Standard	67	48	71·6%
5-day Concomitant	67	43	64·2%	7·4%	−10·6%, 25·5%
10-day Sequential	65	44	67·7%	3·9%	−15·5%, 23·4%

P-value for Chi-squared drop-in-deviance test for significance of interaction with treatment regimen in a logistic regression model controlling for main effects of treatment and baseline covariate